Barbara Boyd Discusses G20 Outlooks – Abundance Mindset ‘Build More Pies’ (Bessent) -vs- Scarcity Mindset ‘Divide Up Pie’ (Europe)

August 31, 2026 | Sundance |

What Barbara Boyd describes in this video about the ideological differences in the G20 reminds me of the long battles around MAGAnomics.

One mindset is based on despair, the scarcity mentality, and says there is a limited about of economic pie and it must be divided by government to ensure equitable distribution (Europe/Obama). The other mindset is based on faith, an abundance mentality, and says we should create, innovate, build and expand economic activity to create more pies (MAGA/Trump).

In this Wednesday update, Barbara Boyd previews the G20 meeting in Asheville, framing it as a clash between an agenda centered on physical economic growth—advanced by Treasury Secretary Scott Bessent—and what she calls the G20/EU’s long-running Malthusian, “green” framework that followed the 2008 financial collapse, bank bailouts, and a shift toward climate policies.

The episode contrasts Trump-era priorities—domestic manufacturing, supply-chain self-sufficiency, critical minerals, energy expansion, workforce upskilling, and new nuclear plans for shipping outlined by Energy Secretary Chris Wright—with European leaders’ efforts to build a “middle powers” bloc and “redirect” citizens’ savings into EU-directed investment. Boyd argues EU priorities include Ukraine war funding, the green transition, and open borders/free trade, and says the outcome of this fight will shape the future ahead of the midterms.

While America Builds, Europe Schemes To Rob Its Citizens

In this Wednesday update, Barbara Boyd previews the G20 meeting in Asheville, framing it as a clash between an agenda centered on physical economic growth—advanced by Treasury Secretary Scott Bessent—and what she calls the G20/EU’s long-running Malthusian, “green” framework that followed the 2008 financial collapse, bank bailouts, and a shift toward climate policies. The episode contrasts Trump-era priorities—domestic manufacturing, supply-chain self-sufficiency, critical minerals, energy expansion, workforce upskilling, and new nuclear plans for shipping outlined by Energy Secretary Chris Wright—with European leaders’ efforts to build a “middle powers” bloc and “redirect” citizens’ savings into EU-directed investment. Boyd argues EU priorities include Ukraine war funding, the green transition, and open borders/free trade, and says the outcome of this fight will shape the future ahead of the midterms.

14:32

https://theconservativetreehouse.com/blog/2026/08/31/barbara-boyd-discusses-g20-outlooks-abundance-mindset-build-more-pies-bessent-vs-scarcity-mindset-divide-up-pie-europe/

https://youtu.be/p64n42Q8ZY0

Loss of cheap energy harmed EU economy – von der Leyen

The bloc saw oil and natural gas prices soar after it drastically reduced Russian imports over the Ukraine conflict

Published 28 Aug, 2026 02:41

European Commission President Ursula von der Leyen has acknowledged that the loss of cheap energy imports has dealt a blow to the EU economyand that the bloc now faces prices far above those of its main competitors.

The EU drastically reduced Russian oil and gas imports following the escalation of the Ukraine conflict in 2022,while Brussels has committed to completely phasing out Russian fossil fuels by 2027. Energy costs have since surged across much of the bloc, with the US-Israeli war on Iran adding further pressure.

Speaking at the La Rencontre des Entrepreneurs de France (REF) business conference in Paris on Thursday, von der Leyen said that “for a long time, the European economic model relied on”several key factors, including inexpensive energy imports. However, the pillars that once underpinned the bloc’s prosperity have now “disappeared,” she added.

Without addressing the reasons behind the rise in energy costs, von der Leyen noted that“European prices remain two to three times higher than in the United States and China.”

German Chancellor Friedrich Merz acknowledged last month that Berlin’s self-imposed embargo on Russian energy was the main cause of the “ongoing energy crisis” that has eroded the competitiveness of German industry.Before 2022, Russia supplied approximately 55% of Germany’s natural gas imports.

French President Emmanuel Macron similarly warned earlier this year that the EU was in “emergency mode” over soaring energy costs after replacing Russian pipeline gas with more expensive liquefied natural gas (LNG) from the US.

The Financial Times reported in June, citing projections by consultancy Wood Mackenzie, that the EU could enter the coming heating season with its lowest gas reserves in 15 years.

Some member states have since balked at further restrictions on Russian LNG as Brussels pushes to end long-term imports beginning next year.Against this backdrop, the bloc has recently stepped up purchases of Russian LNG, Bloomberg reported earlier this month.

Despite the resistance and renewed purchases, the European Commission has maintained that it will proceed with the total phase-out of Russian energy imports, even in the event of physical shortages or the threat of power cuts.

Moscow has repeatedly described EU sanctions, particularly those targeting its energy sector, as self-defeating measures that undermine the bloc’s competitiveness.Russia, meanwhile, has redirected much of its energy exports elsewhere, primarily Asia.

https://www.rt.com/business/644742-energy-loss-eu-economy-leyen/

Trump Reaches Deals with Nine More Pharmaceutical Companies

Nick Gilbertson31 Aug 2026

President Donald Trump has struck deals with nine more pharmaceutical companies to slash drug prices for patients.

Trump announced the deals with Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB on Monday in the Oval Office while flanked by pharmaceutical executives.

“I’m thrilled to announce a major expansion of one of our signature affordability initiatives, something that people have been trying to get for years, for decades, and I’m not even sure that other presidents tried,” Trump said of his most favored nation (MFN) drug pricing initiative.

“Nine new pharmaceutical companies are committing to deliver their lowest drug prices for American patients,” he added.

The agreements ensure that every state Medicaid program will have access to MFN drug prices for all nine companies’ products, which the White House projects will save Americans across the country billions of dollars.

Moreover, the deals will lower costs “on drugs that treat numerous costly, chronic, and even rare diseases, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions, and various forms of cancer,” per the White House. All new innovative medicines the companies launch are guaranteed to have MFN pricing.

Additionally, the companies have committed to invest a collective $19.6 billion for U.S. manufacturing, and some companies are donating a substantial amount of ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), according to the White House;

UCB will contribute 163 tons of levetiracetam, an anticonvulsant used to control and prevent certain types of seizures, to the SAPIR.

Sun Pharma will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline; both antibiotics to treat bacterial infections, to the SAPIR.

Teva Pharmaceuticals will contribute 45 metric tons of metronidazole, an antibiotic and antiprotozoal used to treat certain bacterial and parasitic infections, and 4.8 tons of amlodipine, an antihypertensive drug, to the SAPIR.

Astellas will contribute 25 kg of tacrolimus, an immunosuppressant used to prevent organ rejection in people who have had organ transplants, to the SAPIR.

These mark the 18th-26th MFN deals that Trump has secured since last fall, and nearly 90 percent of the branded drug market is included in the agreements, per the White House. Other pharmaceutical companies that have agreed to MFN deals include AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Regeneron, Sanofi, Johnson & Johnson, and AbbVie.

https://www.breitbart.com/politics/2026/08/31/trump-reaches-deals-with-nine-more-pharmaceutical-companies-to-slash-drug-prices/